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OncologyAbstract Background and purpose: Combined PET/CT using 18F-FDG is widely used in evalua-
tion of various malignancies; in their initial staging and more efﬁciently in their follow up; hence,
the importance of evaluation of its diagnostic role in the imaging of skeletal metastases. The pur-
pose of this study is to evaluate precisely the efﬁciency of FDG PET/CT in detection and charac-
terization of osseous metastatic lesions compared to isolated PET and CT in various malignancies.
Patients and methods: The study included 123 patients divided into seven groups of malignancies to
whom PET/CT was done. In this study population, a detailed retrograde lesion based analysis was
performed for a total of 1705 detected bone lesions on PET, CT and fused PET/CT images. Sensi-
tivity, speciﬁcity, PPV and NPV of each modality were calculated. Semi-quantitative and ROC
curve analysis of the lesions were performed to study the relationship between the lesion’s SUV
and its corresponding morphologic pattern on CT and to set a reliable SUVmax cut-off value that
can predict the presence of malignant lesion.
Results: The calculated fused PET/CT sensitivities and speciﬁcities in various malignancies ranged
from 95.2% to 99.6% and 75% to 100%, respectively. The combined PET/CT has signiﬁcantly
improved the low CT sensitivity (especially in lymphoma) as well as both CT and PET speciﬁcities.
182 A. Wafaie et al.Our ROC analysis suggested using SUVmax of 3 as a cut off value for malignant osseous lesions.
Conclusion: Fused PET/CT was highly efﬁcient in evaluation of skeletal metastases with superior
performance in: detection of early bone marrow inﬁltration not apparent on CT, resolution of met-
abolic activity before deﬁnite signs of complete healing on CT, detection of missed sclerotic metas-
tases on PET due to their relatively low metabolic activity, detection of intra and extra osseous
recurrence and differentiation of benign from malignant bone lesions.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
Positron emission tomography (PET) is a molecular imaging
technique most widely applied in oncology, using 18F labeled
ﬂuorodeoxyglucose (18F-FDG). It provides quantitative and
qualitative functional information about tumor cells depending
on their increased rate of glucose metabolism. 18F-FDG PET is
regarded to be effective in the detection, staging and restaging of
malignancies with a remarkably high sensitivity. The combina-
tion of PET and computed tomography (CT) represents a very
unique imaging modality that scans the whole body in the same
session, providing functional and anatomic information in co-
registered images. It combines the high sensitivity of PET to
the superior anatomical localization by CT resulting in much
more accurate detection and staging of malignancies (1).
Several studies had illustrated the additional value of PET/
CT scan compared to various imaging modalities in the accu-
rate initial staging and follow up of malignancies. PET/CT
scan is able to identify invisible metastatic lesions not yet
developing into structural changes. Thereby, a signiﬁcant
change in the management plan might be done (2).
CombinedPET/CT iswidely applied in the evaluation of var-
ious malignancies; hence the importance of evaluating its role in
the detection and characterization of skeletal metastases. The
integration of PET and CT in one modality has improved the
diagnostic accuracy of each in the evaluation of malignancies
and nevertheless in the evaluation of skeletal metastases (1).
2. Patients and methods
The study population included 123 cancer patients (57 male
patients, 66 female patients; mean age: 43.3; age range: 14–
85) who underwent whole body combined PET/CT scanning.
The indications for PET/CT examination were variable; 15 pa-
tients were referred for initial disease staging and 108 patients
for follow up at variable disease stages.
We have divided the study population into groups accord-
ing to the type of primary malignancies for more accurate data
analysis. For all patients, the primary malignancy type has
been pathologically proven.
The study excluded those who had recent intervention
(biopsy) or local external beam radiotherapy or granulocyte
colony stimulating factor therapy within 1 month from PET/
CT scan.
2.1. PET/CT technique
Combined PET/CT scan was performed using Siemens
Biograph TruePoint 64; (Siemens Healthcare, Erlangen,Germany). The integrated CT system is a 64 multi-slice scan-
ner. The acquisition of co-registered CT and PET images
was performed in one session.
Adequate patient preparation rules were strictly followed.
Patients were instructed to fast except for glucose-free hydra-
tion for 4–6 h before injection of 18F-FDG. The scan was per-
formed 40–60 min after IV injection of 3.7 MBq/kg;
(maximum dose 370 MBq) equivalent to 0.1 mCi/kg; (maxi-
mum dose = 10 mCi) of 18F-FDG. The patients were exam-
ined in supine position. A whole body examination was
performed starting from skull base to mid thighs.
 A PET emission scan was performed over several bed posi-
tions (5–7), each with an axial ﬁeld of view of approxi-
mately 15 cm per bed position with an in-plane spatial
resolution of 4 mm covering the same ﬁeld of view as with
CT. The acquisition time of emission data was 2 min per
bed position in the two dimensional mode. The total exam-
ination time range was between 13 and 17 min.
 A fully diagnostic CT scan was performed using the follow-
ing parameters: 350 mA, 120 kV, 0.5 s tube rotation time,
slice thickness 5 mm, 8-mm table feed and 3 mm incremen-
tal reconstruction. IV contrast administration (80–120 mL
of a low-osmolarity iodinated contrast agent (Ultravist
300,Schering, Berlin, Germany) and negative oral contrast
agent (water) for bowel were used.
Images were reconstructed and viewed on workstation (Syn-
go Multimodality Workplace, Siemens Medical Solutions),
which provided multi-planar reformatted PET, CT and fused
PET/CT images with linked cursors as well as 3D maximum
intensity projection images (MIP) PET images in video mode.
2.2. Image analysis
The PET images were reviewed by one experienced nuclear
medicine physician. The CT images were analyzed separately
by two experienced radiologists; each was blind to the other’s
ﬁndings. Fused PET/CT images were then analyzed separately
by each of the three. In case of CT images, if the recorded ﬁnd-
ings or estimated score by the two radiologists were not the
same, they had to reach a consensus together. While for fused
PET/CT images, if the interpreted ﬁndings by any of the three
readers were not the same, we approved the opinion agreed
upon by at least two of them.
The presence of bone metastases was conﬁrmed by biopsy
or sequential various imaging modalities including CT, PET/
CT, magnetic resonance imaging (MRI); performed during a
follow up of at least 6 months. In some cases reviewing previ-
ous scans was also done to correlate recorded lesions.
Table 2 CT scores for bone lesions.
CT score Morphologic appearance
1 No morphologic changes
2 Benign looking lesions
3 Equivocal lesions
4 Malignant looking lesions
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Analysis of PET images was done via visual and semi quanti-
tative assessment (SUVmax measurement). Positive lesions were
recorded at areas of high FDG uptake. The standardized
uptake value (SUVmax) was measured at each lesion and
compared to background activity. The standard background
activity was measured at the liver, right lobe. In patients
having diseased liver, the background activity was measured
at the mediastinal blood pool. Accordingly a scoring system
was applied (Table 1).
At ﬁnal diagnosis, true positive lesions were those with PET
score >3 and conﬁrmed as active bone metastases by biopsy
or on follow up imaging (whether they show a corresponding
morphologic changes on CT or not). Lesions with score 2 or
3, or have been missed on current scan and proved to be malig-
nant as evidenced by progression on follow up images, were
considered false negative. Lesions which have been missed
being outside PET/CT scan ﬁeld and detected on other imag-
ing modalities were also considered false negative.
PET recorded lesions were considered false positive if up-
take has been localized extra-osseous on corresponding fused
PET/CT images or a lesion with score >3 appeared to be
benign on fused PET/CT images or other imaging modalities
and conﬁrmed by biopsy or on further follow up images. True
negative lesions were those lacking appreciable uptake on PET
(score 1), though looking malignant on corresponding CT
images, and conﬁrmed as healed inactive lesions when corre-
lated to previous scans and follow up images and lesions with
score 63 and proved to be benign on fused PET/CT images or
other imaging modalities and conﬁrmed on further follow up
images.
4. CT images
The whole CT images were reviewed in bone as well as soft tis-
sue windows. Detected areas of abnormal FDG uptake on
PET images were, in particular, further analyzed on CT
images. Bone lesions were classiﬁed into benign and malignant
looking lesions according to their morphologic appearance.
Some lesions which did not meet the criteria of either were con-
sidered equivocal. Accordingly, a scoring system was also per-
formed for the lesions (Table 2).
Bone lesions were considered benign according to the fol-
lowing criteria: being well deﬁned, homogenously and fully
sclerotic, and lytic with regular sclerotic margins. Localization
to the vertebral end plates or articular surfaces was also con-
sidered a benign feature.
Bone lesions were considered malignant if appeared ill
deﬁned, irregularly or heterogeneously sclerotic, lytic withTable 1 PET scores for bone lesions.
PET
score
FDG uptake
1 No appreciable FDG uptake by visual assessment
2 Notable FDG uptake, SUVmax < liver uptake
3 Notable FDG uptake, SUVmax = liver uptake (range: ±10%)
4 Intense diﬀuse FDG uptake, SUVmax > liver uptake
5 Intense focal FDG uptake, SUVmax > liver uptakeirregular sclerotic margins, associated with cortical destruction
or extra osseous soft tissue component.
At ﬁnal diagnosis, true positive lesions were those assigned
as score 4 and conﬁrmed as active bone metastases by biopsy
or on follow up imaging. Lesions with score <4 or have been
missed on current scan and proved to be malignant on follow
up images, were considered false negative. Lesions with score 1
which show uptake on corresponding fused PET/CT images
and proved to be malignant by biopsy or on follow up images
were also considered false negative lesions.
The CT recorded lesions were considered false positive if a
malignant looking lesion (score 4) did not show appreciable
uptake on corresponding fused PET/CT images and proved
to be a healed inactive bone metastasis when correlated to pre-
vious scans and follow up images. True negative lesions were
those with score 2 or 3 and proved to be benign on follow
up imaging.
5. Fused PET/CT images
On interpreting fused PET/CT images, lesions were considered
positive (active bone metastases) when areas of increased FDG
uptake (>liver or mediastinal blood pool) are localized to
bone whether showing corresponding morphologic changes
or not. Lesions were considered negative for active bone
metastases at areas lacking high FDG uptake (6liver or medi-
astinal blood pool) despite suspicious corresponding CT ﬁnd-
ings if any.
At ﬁnal diagnosis, true positive lesions were those recog-
nized as active metastases and conﬁrmed by biopsy or on fol-
low up imaging. Lesions which have been missed on current
scan and proved to be malignant on follow up images were
considered false negative. Lesions which have not been re-
corded, being outside the scan ﬁeld (e.g. calvarial bones or at
the extremities), were also considered false negative lesions.
Fused PET/CT recorded lesions were considered false posi-
tive if a lesion has been considered as active metastasis and
proved to be benign by biopsy or follow up imaging. True
negative lesions were those recognized as benign lesions and
conﬁrmed so by different imaging modalities on follow up
imaging. Also lesions which have been recognized as inactive
healed metastases and conﬁrmed when correlated to previous
scans and follow up imaging were also considered true nega-
tive lesions.
5.1. Statistical analysis
Data were tabulated and digitalized on a personal computer
using Microsoft Excel for Mac version 14.0.0 spreadsheet
program. Discrete data are presented as mean ± standard
deviation. Categorical data are presented as percentage.
Descriptive statistics, calculation of the true and false positive
184 A. Wafaie et al.and negative cases is made using the statistical capabilities of
the same Microsoft excel program. Sensitivity, speciﬁcity, po-
sitive and negative predictive values as well as the receiver
operator characteristic (ROC) analysis were calculated using
either the Microsoft Excel or the OpenEpi program, A Collab-
orative, Open-Source Project in Epidemiologic Computing
Version 3 May 2009.
6. Results
The study included 123 patients (57 male patients, 66 female
patients). Their age range is 14–85 years; with mean age:
43.3 years ± 16.22 (SD). The study population composes 7
groups of different primary malignancies (Table 3).
All the bone lesions (1705 lesions) were separately analyzed
on PET, CT and fused PET/CT images in each of the 7 groups
(Fig. 1). According to the designed PET scoring system, all le-
sions with score 4 or 5 were considered positive for metastases.
According to the designed CT scoring system, all lesions with
score 4 were considered positive for metastases.
Tables 4–6 demonstrate the number of true positive (TP),
true negative (TN), false positive (FP) and false negative
(FN) lesions as well as the sensitivity, speciﬁcity, positive pre-
dictive value (PPV) and negative predictive value (NPV) for
PET, CT and combined PET/CT, respectively.
Five false negative lesions on PET, CT and fused PET/CT
images were bone metastases that have been missed being out-
side the scan ﬁeld (e.g. at the skull bones and at the long bones
peripherally) and have been detected by other imaging
modalities.
On PET images, the false negative lesions also included le-
sions of low to moderate metabolic activity (score 63). False
positive lesions on PET images included benign bone lesions
of high metabolic activity (score >3) (e.g. fractures in acute
stage) and focal areas of intense uptake at soft tissue in close
proximity to bone and misinterpreted as bone metastases due
to lack of proper anatomical localization (e.g. metabolically
active lymph nodes adjacent to vertebrae). For such false posi-
tive PET lesions, fused PET/CT images was much more help-
ful, it accurately detected extra osseous uptake guided by
anatomical localization on CT images with no confusion.
On CT images, there was a considerably large number of
missed (false negative) lesions due to absence of any detectable
structural abnormalities, however, a high metabolic activity of
such lesions allowed their proper detection on fused PET/CT
images. Almost all of the false positive lesions on CT images
were malignant looking (score 4) while being metabolicallyTable 3 The study population, composed of 7 groups of different
Primary malignancy No. of patients Sex Age
M F x SD
Breast 39 1 38 49.33 11.77
HD 31 20 11 31.19 12.43
NHL 30 22 8 46.66 15.47
Colon 8 4 4 47.5 13
Primary bone tumors 8 5 3 29.37 19
Renal 4 2 2 50.75 13
Bronchial 3 3 0 72.33 11.67
Total 123 57 66 43.3 16.22inactive (absent FDG uptake on PET and fused PET/CT
images) representing healed bone metastases.
Fused PET/CT images had much less false results com-
pared to either of its components alone. Fused PET/CT images
missed lesions which were located outside the routine PET/CT
scan ﬁeld and those were few and were not solitary metastasis.
In our study, false positive lesions on fused PET/CT images
were bone fractures in their acute stage, these had shown a
high metabolic activity (measured SUVmax was higher than
the background uptake).
Fused PET/CT images allowed accurate localization of up-
take (osseous versus extra osseous), identiﬁcation of healed
bone metastases as such by the absence of uptake as well as al-
lowed detection of early bone marrow inﬁltration before struc-
tural changes are apparent on CT images.
The sensitivity of PET ranged from about 86% to 98%. It
was lowest in the breast cancer group due to the presence of
considerably large number of false negative lesions (n= 47),
4 lesions outside the scan ﬁeld and 43 missed lesions with score
3. These 43 lesions have progressed in the follow up studies.
The speciﬁcity of PET ranged from about 25% to 95%. It
was lowest in the colon cancer group due to the presence of rel-
atively large number of false positive lesions (n= 6 out of 75),
4 misinterpreted lesions as bone metastases while being nearby
metabolically active nodal and pleural deposits and 2 benign
lesions (one was a rib fracture and the other was a vertebral
body wedge fracture in acute phase with score >3).
The sensitivity of CT ranged from about 7% to 95%. It was
lowest in the Non Hodgkin’s lymphoma and Hodgkin’s dis-
ease (NHL and HD) groups due to the presence of consider-
ably large number of false negative lesions (n= 238 and
447). The vast majority of these lesions showed no structural
CT abnormalities (Fig. 2). The speciﬁcity of CT ranged from
about 25% to 100%. It was lowest in the breast cancer group
due to the presence of relatively large number of false positive
lesions (n= 145 out of 526), all were malignant looking (score
4) while being metabolically inactive, absent FDG uptake on
PET, and proved to be healed metastases. The highest CT sen-
sitivity (95%) was noted in the bronchial cancer group, while
the highest CT speciﬁcity (100%) was noted in the bronchial,
renal and colon cancer groups where no false positive lesions
were interpreted on CT.
The combined PET/CT showed the highest sensitivity in all
of the 7 groups compared to isolated PET and CT, ranging be-
tween 95.2% and 99.6% (Fig. 3). The speciﬁcity of fused PET/
CT was also high ranging from 75% to 100%. It was lowest in
the colon cancer group due to the presence of 2 false positiveprimary malignancies.
No. of analyzed lesions No. of conﬁrmed active bone metastases
526 333
604 542
323 261
75 67
67 47
66 63
44 42
1705 1355
Fig. 1 Number of conﬁrmed active bone metastasis in each group compared to the total number of analyzed lesions.
Table 4 PET ﬁndings and statistics in each of the 7 groups.
PET TP TN FP FN Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
Breast 286 184 9 47 85.88 95.33 96.94 79.65
HD 533 37 25 9 98.33 61.29 95.69 80.85
NHL 254 51 11 7 97.31 82.25 95.84 87.93
Colon 58 2 6 9 86.56 25 90.6 18.18
Primary bone tumors 46 16 4 1 97.87 80 92 94.11
Renal 62 1 2 1 98.41 33.33 96.87 50
Bronchial 40 1 1 2 95.23 50 97.56 33.33
Table 5 CT ﬁndings and statistics in each of the 7 groups.
CT TP TN FP FN Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
Breast 184 48 145 149 55.25 24.87 55.92 24.36
HD 95 27 35 447 17.52 43.54 73.07 5.69
NHL 18 43 19 243 6.89 69.35 48.64 15.03
Colon 22 8 0 45 32.83 100 100 15.09
Primary bone tumors 18 5 15 29 38.29 25 54.54 14.7
Renal 23 3 0 40 36.5 100 100 6.97
Bronchial 40 2 0 2 95.23 100 100 50
Table 6 Combined PET/CT ﬁndings and statistics in each of the 7 groups.
PET/CT TP TN FP FN Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
Breast 329 190 3 4 98.79 98.44 99.09 97.93
HD 540 62 0 2 99.63 100 100 96.87
NHL 256 59 3 5 98.08 95.16 98.84 92.18
Colon 65 6 2 2 97.01 75 97.01 75
Primary bone tumors 46 18 2 1 97.87 90 95.91 94.73
Renal 62 3 0 1 98.41 100 100 75
Bronchial 40 2 0 2 95.23 100 100 50
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was considered despite of their CT appearance. The highest
PET/CT speciﬁcity (100%) was noted in the bronchial, renal
cancer (Fig. 4) and HD groups.We performed a semi-quantitative analysis of lesions de-
tected on PET/CT. SUVmax has been measured for each lesion.
The relationship between the lesion’s SUV and its correspond-
ing morphologic pattern on CT has been studied. We found
Fig. 2 A male patient with NHL (A) MIP PET image reveals multiple focal areas of intense uptake denoting lymphomatous inﬁltrates.
The axial CT and fused PET/CT images show: Multiple lymphomatous bony deposits at the sternum, right ribs and dorsal vertebral body
with a left paratracheal lymph node (B), lumbar vertebral body with aortocaval and retrocaval lymph nodes (C) and right ischium (D). All
the lymphoma bony deposits in this patient did not show any morphologic CT changes.
186 A. Wafaie et al.that the lesions of highest SUVmax were the lytic bone lesions
followed by those of absent morphologic changes. The lesions
of lowest SUVmax were the sclerotic lesions. The bone lesions
of mixed patterns lied in between (Fig. 5). Furthermore, the
cut-off value of the SUVmax that can predict the presence of
malignant lesion was evaluated by the ROC curve analysis.Fig. 3 A male patient with HD: axial CT (left), axial fused PET/CT
with surrounding patchy sclerosis is noted at the left side of L2 vertebra
has increased, lytic changes has decreased with resolution of correspon
On further follow up, sclerosis has increased with no corresponding FD
right pedicle is noted.It has been shown that both an SUVmax > 2 and >3 have high
sensitivity to detect malignant lesions (99.7% and 97%, respec-
tively); however with a higher speciﬁcity if the cut-off value
was set at 3 (69.4% versus 54.2%). Both values have shown
a high positive and negative predictive values and a very low
bias index.(middle) and axial PET (right) images; (A) a centrally lytic lesion
l body with high FDG uptake. (B) On the follow up scan, sclerosis
ding FDG uptake, the lesion becomes metabolically inactive. (C)
G uptake but a newly developed metabolically active lesion at the
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The study population included a total number of 123 cancer
patients. A total number of 1705 bone lesions were separately
analyzed on PET, CT and fused PET/CT images. At ﬁnal diag-
nosis, 1355 were conﬁrmed to be actual bone metastases. We
performed a separate analysis for data interpreted on PET, CT
and fused PET/CT images in order to evaluate and compare
the diagnostic accuracy of each imaging modality and evaluate
the added value of combined PET/CT imaging in the detection
and characterization ofmetastatic bone lesions. Althoughmany
studies had evaluated the diagnostic accuracy of FDG-PET in
bone metastases (3–8), few had performed such a comparative
analysis for the three components in the same study especially
regarding the evaluation of CT scan alone (9,10). We preferred
to analyze the data separately in each primary malignancy for
a better insight into the nature of each primary malignancy
respecting their different behavior and metabolic activity.
The performed CT scoring system in our study categorized
the detected lesions according to the diagnostic possibilitiesFig. 4 A male patient with renal cell carcinoma. (A) Coronal CT an
metabolically active mass lesion inﬁltrating the surrounding fat planes
CT and fused PET/CT images showing bilateral ischium bones metab
Axial CT and fused PET/CT images showing a cortical lytic lesion at(either malignant or not) to obtain a more accurate evaluation
of the efﬁciency of CT in the characterization of lesions in
oncology patients. The PET scoring system categorized the
lesions according to their visually inspected uptake in compar-
ison to the background uptake and then only those with
detectable uptake higher than that of the background were
considered deﬁnitely malignant. Accordingly, a considerable
number of metabolically active bone metastases were missed
and have been considered false negative thereby underestimat-
ing PET sensitivity. That is why it is worth to mention that
when bone lesions having a PET score P3 also recorded as
positive; the estimated PET sensitivity was higher but on the
expense of lowering PET speciﬁcity. The same was also true
for equivocal bone lesions having a CT score 3. Recording
such lesions as positive increases the sensitivity of CT but on
the expense of lowering the speciﬁcity.
The routine PET/CT scan ﬁeld covers the skull base down
to mid thighs. This resulted in missing few metastatic bone le-
sions (4 in breast cancer and 1 in NHL patients groups) located
at the skull calvarium and femoral condyles. It is noted thatd (B) axial fused PET/CT images showing right renal lower polar
. A left para aortic metastatic lymph node is also noted. (C) Axial
olically active lesions with mild lytic changes at the right one. (D)
the right proximal femoral shaft with intense FDG uptake.
188 A. Wafaie et al.these lesions were not the only metastatic bone lesions in the
studied patients and here we agree with Fujimoto et al. (5) that
such a limitation is not a major drawback, however, it may be
wise to extend the scan ﬁeld to cover the skull especially in
breast cancer patients where skull metastases are rather more
common.
In our study, CT shows low sensitivity in the detection of
bone metastases, explained by the large number of bone metas-
tases which do not show morphologic changes. This was espe-
cially true in lymphoma patients, where the estimated CT
sensitivities were 6.89% and 17.52% in HD and NHL patients
respectively. The integration of PET and CT has notably im-
proved the sensitivity of CT through detection of high FDG
uptake by bone marrow based metastatic cells which are not
associated with structural bone changes; neither destructive
nor osteoblastic. This goes in concordance with the results of
previous studies. Nakamato et al. (11) stated that among true
positive bone metastases seen at PET, morphologic changes at
CT were observed in only half. Evangelista et al. (12) also sta-
ted that PET/CT yielded accurate results in the early detection
of bone marrow metastases in breast cancer, lymphoma as well
as multiple myeloma. Schaefer et al. (13) also encouraged the
superiority of PET/CT compared to CT alone or in combina-
tion with bone marrow biopsy in lymphoma. The bronchial
cancer group was the only exception in our study where the
estimated CT sensitivity is 95.28%. This is actually because
all the analyzed bone lesions in this small group of patients
had corresponding structural changes either of lytic or mixed
pattern.
Regarding CT speciﬁcity, almost all false positive lesions on
CT images in our study were in fact healed metastases. This
was more evident in breast cancer patients, where a large num-
ber of this group population was referred for follow up at a
regressive disease course explaining the notable low speciﬁcity
of CT (24.87%) and high speciﬁcity of PET (95.33%) in this
group. Here the integration of PET and CT signiﬁcantly im-
proved the speciﬁcity of CT and the accuracy of diagnosis
through identifying metabolic inactivity regardless the suspi-
cious or malignant looking CT appearance. We agree with
Tiara et al. (14) emphasizing the inﬂuence of chemotherapy
on the PPV of PET and CT interpretation and the importance
of prior knowledge of treatment history. The calculated speci-
ﬁcity of CT images alone was 100% in the colon cancer, renal
cancer and bronchial cancer groups. It perfectly localized
FDG uptake to bone and could identify all benign lesions inFig. 5 The relationships between SUVmax of bone lesions onthese groups. This was a perfect performance compared to
the much lower calculated CT speciﬁcities in the other groups
reﬂecting the difference in the number of patients in each
group and the number of the analyzed bone lesions with a sub-
sequent higher possibility of false positive results in larger
groups especially in patients having variably healed metastatic
lesions.
Regarding the calculated CT versus combined PET/CT
speciﬁcities in colon cancer patients, we would like to explain
why that of PET/CT was exceptionally lower than CT. This
was because of two benign lesions which were accurately
detected as benign (negative) on CT alone, however according
to our methodology we considered lesions with higher uptake
than the background to be positive on fused PET/CT ignoring
their morphologic CT criteria.
The results of our study agree with the results of previous
studies by Yang et al. (9) and Liu et al. (10) in showing that
CT as an imaging modality is more speciﬁc than sensitive
and that its integration with PET in combined PET/CT im-
proved both its sensitivity and speciﬁcity; however variable
the calculated ﬁgures are. Yet such improved performance
by combined PET/CT is more notable in our results.
We would like to elaborate that a variety of benign lesions
have been analyzed in our study, including vertebral body
haemangiomata, osteoid osteoma, schmorl’s nodes, fractures,
spondylosis, osteoarthritis, avascular necrosis, bone cyst and
bone islands. All these lesions were correctly identiﬁed on
CT. On the other hand, PET was false positive in 3 rib frac-
tures in the breast cancer patients group, 3 rib fractures in
the NHL patients group, 1 rib and 1 vertebral body fractures
in the colon cancer patients group and in periprosthesis inﬂam-
matory/infective process in a case of osteosarcoma. In our
study, we relied on the recorded FDG uptake value (SUVmax)
considering those more than the liver as positive at both PET
and fused PET/CT images, ignoring other criteria of uptake
(e.g. being diffuse or focal) and their corresponding CT
appearance. That was the source of false interpretation of
these benign lesions (false positive results) on PET and fused
PET/CT images. According to our experience in the studied
lesions, we found that considering the CT criteria of these
lesions will largely eliminate false results. In fact all falsely re-
corded benign lesions in our study on PET and fused PET/CT
images were identiﬁed as benign on CT component regardless
their uptake value. Lack of bony expansion and soft tissue
components on CT images strongly predicted the benignPET and their corresponding morphologic pattern on CT.
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tissue windows. We agree with Shin et al. (15) in his study
showing a pathological fracture as having central medullary
high uptake. In our study, falsely recorded benign fractures
as malignant, though having high FDG uptake higher than
the liver, yet such uptake was linear and diffuse rather than fo-
cal in appearance and largely cortical rather than medullary.
These benign lesions with high uptake were not the only
source of false positive PET lesions. In fact a major source
of false positive PET lesions was focal uptake at soft tissue
lesions in close proximity to bone. These were frequently
encountered in all studied groups, yet most numerous in
lymphoma (HD>NHL) due to nodal involvement in close
proximity to the vertebrae. The prevalence of such false
positive lesions in different groups reﬂects the variable calcu-
lated PET speciﬁcities being least in colon, renal and bronchial
cancer groups (25%, 33.33% and 50%, respectively) having
the least number of analyzed lesions. The breast cancer group
was an exception in showing a much higher calculated PET
speciﬁcity (95.33%) attributed to the large number of metabol-
ically inactive healed metastases recorded as true negative
while having suspicious malignant looking CT appearance.
The results of our study show that PET had variably high
sensitivities ranging from 85.88% to 98.41%; these ﬁgures
are much higher compared to CT sensitivities but are slightly
less than or even equal to fused PET/CT sensitivities. Yet
the integration of PET and CT notably improved PET speciﬁc-
ities in all groups. The previous studies also had similar results
regarding the high estimated PET sensitivities as in Chang
et al. (3), Qu et al. (6), Wu et al. (8), Liu et al. (10), Abe
et al. (16), Kato et al. (17), Wu et al. (18) and Yang et al.
(19). These studies also showed a similar improved speciﬁcity
for combined PET/CT compared to PET alone.
According to the results of our study, the interpretation of
fused PET/CT images had overall more accurate results than
the interpretation of PET or CT images alone. The estimated
PET/CT sensitivities in different groups ranged from 95.23% to
99.63% while the estimated PET/CT speciﬁcities in different
groups ranged from 95.16% to 100%. In fact the integration of
PET/CTgreatly improved the sensitivity ofCTand the speciﬁcity
of PET. Fused PET/CT images will have almost perfect results
when considering the integrated information from both modali-
ties PET and CT and especially respecting CT criteria regardless
the FDGuptake value in evaluating likely benign osseous lesions.
We studied the relationship between FDG uptake and the
morphologic nature of bone lesions. A semi quantitative anal-
ysis was performed through measuring SUVmax at each lesion.
Lesions having highest average values of SUVmax were lytic
bone metastases (8.42) followed by those of no corresponding
morphologic changes (8.37). Sclerotic bone metastases showed
lower average values of SUVmax (2.37). Sclerotic bone metasta-
ses were detectable on PET/CT scan, though showing lower
values of FDG uptake yet appreciable visible uptake is noted.
The integration of PET and CT further limits the possibility of
missing such lesions being readily visible on CT images. We
agree with Koolen et al. (20) that it is not so much the type
of metastasis (sclerotic or lytic), but possibly the characteristics
of the primary tumor or treatments prior to the PET/CT scan
might inﬂuence the degree of FDG uptake of bone metastases.
We believe that lower SUVmax by these lesions reﬂects lower
metabolic activity of individual cancer lesions which in turn
is associated with more osteoblastic reaction.We also performed a ROC analysis for recorded SUVmax at
benign and malignant bone lesions as an attempt to estimate a
cut off value. We found that the best diagnostic accuracies
were obtained at SUVmax 2 and 3 with sensitivities 99.7%
and 97%, respectively and speciﬁcities 54.2% and 69.4%,
respectively. In our opinion we prefer using SUVmax 3 rather
than 2 as a cut off value because of much improved speciﬁcity.
The difference in the calculated sensitivities is rather small
compared to the difference in their speciﬁcities and since the
main limitation of PET is its speciﬁcity, we prefer using
SUVmax 3. In our study, we wanted to make the best of our
analyzed data and to propose this as a guide in confusing
cases. However as previewed literature (21) emphasized the
importance of cautious use of any published cut off values,
we also do. Yet this may be of value in some limited confusing
cases. We also believe that the integration of PET and CT data
interpretation largely limits the diagnostic challenge of benign
versus malignant.
8. Conclusion
In combined PET/CT, CT images signiﬁcantly improve PET
speciﬁcity with better localization of bone metastases and dif-
ferentiation between benign and malignant lesions. On the
other hand, PET can detect bone marrow based metastases
early and in the absence of morphologic changes on CT
images; thereby improving CT sensitivity. The inﬂuence of
the integration of PET and CT upon CT speciﬁcity is also
notable in cases of treated healed metastases which lack meta-
bolic activity in spite of suspicious morphologic appearance.
The estimated fused PET/CT sensitivities and speciﬁcities in
our study population ranged from 95.2% to 99.6% and from
75% to 100%, respectively. The fused PET/CT sensitivities
were higher than or equal to PET sensitivities but they were
much higher than CT sensitivities especially in the lymphoma
groups. The fused PET/CT speciﬁcities also showed variably
higher values compared to PET and CT, emphasizing the
important role of combined PET/CT in detection and charac-
terization of bone lesions in cancer patients.
According to our ROC analysis, we suggest using SUVmax 3
as a cut off value for malignant osseous lesions. However, it
should be used with caution in some limited confusing cases.
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